Pular para o conteúdo
Radio Logo
PodcastsMedicinaEuropean Society for Vascular Surgery

European Society for Vascular Surgery

European Society for Vascular Surgery
Último episódio

223 episódios

  • European Society for Vascular Surgery

    Oncovascular Surgery: The Essentials with P. Vikatmaa - #ESVS2026

    12/11/2026 | 15min
    Recorded at the ESVS Annual Meeting in Belgrade, this episode features Joanna Halman in conversation with Dr Pirkka Vikatmaa from Helsinki, exploring the essentials of oncovascular surgery and the role of vascular surgeons in cancer care.
    What exactly is oncovascular surgery, and where is the field heading? How are dedicated services established, and what does it take to make them successful? We discuss building multidisciplinary teams, developing the expertise needed, and creating effective collaboration across specialities.
    A practical introduction for vascular surgeons curious about this field and how to get involved.
    For further learning, explore the new educational materials on oncovascular surgery in the ESVS Library.
  • European Society for Vascular Surgery

    Feet Fighter: Below-the-Ankle Revascularisation with L. Patrone - #ESVS2026

    05/11/2026 | 23min
    Recorded live at the ESVS podcast booth during the 40th ESVS Annual Meeting in Belgrade, Dimitrios Liakopoulos talks with Dr Lorenzo Patrone about taking revascularisation below the ankle.
    They cover when pedal arch treatment is truly indicated, and why Lorenzo aims for in-line flow to the wound rather than a complete arch. He explains how he defines success, from the on-table angiogram to wound healing, and why thrombosis is the complication to fear in the foot. He also lays out the essential toolkit for any unit starting BTK and BTA work.
    Lorenzo also talks frankly about when to re-intervene and when to accept a stable ulcer in a frail patient whose pain has gone. He explains why a CTO wire is a drill rather than a crossing wire, and how trainees can build competence below the ankle. Above all, his message is that sharing experience with peers is how all of us get better.
    And before you scrub for your first pedal access, listen for his one-minute rule. It may save you, and your patient, a three-hour afternoon.
  • European Society for Vascular Surgery

    All You Need To Know About Diabetic Heel Ulcer Management with G. Clerici - #ESVS2026

    29/10/2026 | 19min
    Diabetic heel ulcers have a notorious reputation for being difficult to treat. There's nothing worse for a patient than having a chronic festering wound on their heel which makes weight bearing difficult if not impossible and is frequently associated with osteomyelitis and infection. Many of these patients often end up with a major limb amputation. In this episode we are joined by Dr Giacomo Clerici, diabetic foot specialist from Italy who tells us how he approaches this difficult problem. A must listen for all vascular professionals working with diabetic patients!
  • European Society for Vascular Surgery

    Drug eluting technology: is it dangerous and does it even work? A look at the timeline of evidence with Professors Behrendt and Roy

    22/10/2026 | 37min
    Prof. Christian Behrendt (head of the German research association) and Prof. Joy Roy
    (Karolinska Institute) take us on a look back chronologically at the journey
    Paclitaxel has taken us on, from the original mortality scare to landmark trials, we follow
    the twists and turns of the evidence.
    We ask if safety is only half the story and whether it makes sense to judge every
    drug-coated balloon and stent as one big, paclitaxel-coated family, what the emerging
    Limus technologies might bring to the table, and whether industry influence has helped
    shape a debate in which the stakes are anything but theoretical.
    Because ultimately, a beautiful angiogram is lovely. But if our patients aren't walking
    further, living longer, or feeling better, what exactly are we celebrating?
    Join us as we separate the signal from the noise and ask all the uncomfortable
    questions at the heart of it all.
    This episode is supported by Cook Medical
    PAPERS MENTIONED
    1. Katsanos et al. (2018) — Risk of Death Following Application of Paclitaxel-
    Coated Balloons and Stents in the Femoropopliteal Artery of the Leg: A
    Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Read the paper — Journal of the American Heart Association
    2. IMPERIAL trial (2018) — Gray et al. A polymer-coated, paclitaxel-eluting stent
    (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for
    endovascular femoropopliteal intervention: a randomised, non-inferiority trial.
    Read the paper — The Lancet
    3. Katsanos et al. (2026) — Dynamic Risk of Death following Application of
    Paclitaxel Coated Devices in the Femoropopliteal Artery: A Contemporary Meta-
    analysis of Randomised Controlled Trials.
    Read the paper — European Journal of Vascular and Endovascular Surgery
    4. SWEDEPAD 1 (2025) — Paclitaxel-coated versus uncoated devices for
    infrainguinal endovascular revascularisation in chronic limb-threatening
    ischaemia: a multicentre, participant-masked, registry-based, randomised
    controlled trial.
    Read the paper — The Lancet
    5. SWEDEPAD 2 (2025) — Paclitaxel-coated versus uncoated devices for
    infrainguinal endovascular revascularisation in patients with intermittent
    claudication: a multicentre, participant-masked, registry-based, randomised
    controlled trial.
    Read the paper — The Lancet
    6. REALDES — 3-year outcomes (2025) — Shibata et al. Comparative Analysis of
    Three Year Results of Two Paclitaxel Related Stents for the Management of
    Femoropopliteal Disease in a Real World Setting.
    Read the paper — European Journal of Vascular and Endovascular Surgery
    7. REALDES — 1-year outcomes — Shibata et al. One Year Outcomes of Zilver
    PTX Versus Eluvia for Femoropopliteal Disease in Real-World Practice:
    REALDES Study.
    Read the paper — Journal of Endovascular Therapy
    8. Behrendt et al. (2020) — Long Term Survival after Femoropopliteal Artery
    Revascularisation with Paclitaxel Coated Devices: A Propensity Score Matched Cohort
    Analysis. A large German health-insurance database study comparing long-term
    outcomes after paclitaxel-coated and uncoated devices.
    9.Read the paper — European Journal of Vascular and Endovascular Surgery
    10. Nordanstig et al. (2026) — Editor's Choice – Focused Update on Paclitaxel Coated
    Technologies, from the 2024 ESVS Guidelines
    on the Management of Asymptomatic Peripheral Arterial Disease and Intermittent
    Claudication. The updated recommendations reconsider the role of paclitaxel-coated
    devices in intermittent claudication in light of SWEDEPAD 2 and the emerging evidence
    on clinical benefit and long-term safety.
    Read the paper — European Journal of Vascular and Endovascular Surgery
  • European Society for Vascular Surgery

    TEVAR vs Standard Medical Therapy in Uncomplicated Type B Aortic Dissection: A Roundtable with the IMPROVE-AD, EARNEST and SUNDAY Trial Investigators

    16/10/2026 | 54min
    Three trials walk into an aorta and ask what the house recommends. The bartender shrugs: “Sorry, we’re randomising tonight.”
    Three trials. Three leading investigators. One of the biggest unresolved questions in aortic surgery: should patients with uncomplicated type B aortic dissection undergo thoracic endovascular aortic repair (TEVAR), or is best medical therapy the better strategy?
    In this episode of the ESVS Podcast, Safa Riahi brings together Professor Jacob Budtz-Lilly (SUNDAY), Professor Firas Mussa (IMPROVE-AD) and Professor Colin Bicknell (EARNEST), for an in-depth roundtable exploring the rationale, design, and challenges behind three major randomised controlled trials. From differences in patient selection and timing of intervention to aortic remodelling, procedural safety, long-term outcomes, and cost-effectiveness, we examine what each trial hopes to establish and why their results could reshape the management of uncomplicated type B aortic dissection.
    We also discuss the meaning of “uncomplicated,” the limitations of our current evidence, the importance of best medical therapy, and the challenge of communicating genuine clinical uncertainty to patients. Will these trials finally help us identify who benefits from early TEVAR, when to intervene, and whether improved aortic remodelling translates into better outcomes for patients?
    Three trials walk into an aorta. The answers, for now, remain anything but straightforward.
    With: Professor Firas Mussa, Professor Colin Bicknell, and Professor Jacob Budtz-Lilly.
    Trials discussed:
    IMPROVE-AD: https://clinicaltrials.gov/study/NCT06087029
    EARNEST: https://www.isrctn.com/ISRCTN30838068
    SUNDAY: https://clinicaltrials.gov/study/NCT05215587
Mais podcasts de Medicina
Sobre European Society for Vascular Surgery
The ESVS offers resources for vascular surgeons, nurses, trainees and more so we may fulfil our mission of improving vascular health for the public benefit.ESVS has received sponsorship for the inclusion of some topics to be addressed in some podcasts, but the focus, content and development of all podcasts are fully independent.
Site de podcast

Ouça European Society for Vascular Surgery, DrauzioCast e muitos outros podcasts de todo o mundo com o aplicativo o radio.net

Obtenha o aplicativo gratuito radio.net

  • Guardar rádios e podcasts favoritos
  • Transmissão via Wi-Fi ou Bluetooth
  • Carplay & Android Audo compatìvel
  • E ainda mais funções